The historical rank and industry rank for DARA Biosciences's Days Inventory or its related term are showing as below:
FRA:PJUF'
s Days Inventory Range Over the Past 10 Years
Min: 102.06 Med: 190.83 Max: 950.52
Current: 102.06
During the past 13 years, DARA Biosciences's highest Days Inventory was 950.52. The lowest was 102.06. And the median was 190.83.
FRA:PJUF's Days Inventory is not ranked
in the Biotechnology industry.
Industry Median: 193.86
vs FRA:PJUF: 102.06
DARA Biosciences's Days Inventory
declined
from Sep. 2014 (129.89) to Sep. 2015 (84.21).
Inventory Turnover measures how fast the company turns over its inventory within a year.
DARA Biosciences's Inventory Turnover for the
three
months ended in Sep. 2015 was 1.08.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
DARA Biosciences's Inventory-to-Revenue for the
three
months ended in Sep. 2015 was 0.19.
DARA Biosciences Days Inventory Historical Data
The historical data trend for DARA Biosciences's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of DARA Biosciences's Days Inventory
For the Biotechnology subindustry, DARA Biosciences's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DARA Biosciences's Days Inventory Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DARA Biosciences's Days Inventory distribution charts can be found below:
* The bar in red indicates where DARA Biosciences's Days Inventory falls into.
DARA Biosciences Days Inventory Calculation
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
DARA Biosciences's Days Inventory for the fiscal year that ended in Dec. 2014 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DARA Biosciences (FRA:PJUF) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
DARA Biosciences's Inventory Turnover for the
three
months ended in Sep. 2015 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
DARA Biosciences's Inventory to Revenue for the
three
months ended in Sep. 2015 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
DARA Biosciences Days Inventory Related Terms
Thank you for viewing the detailed overview of DARA Biosciences's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
DARA Biosciences Inc was incorporated on June 22, 2002. It is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. Through its acquisition of Oncogenerix, Inc., which occurred on January 17, 2012, the Company acquired exclusive U.S. marketing rights to its first commercial proprietary product, Soltamox (oral liquid tamoxifen). The Company's main focus is on the development and commercialization of oncology treatment and supportive care pharmaceutical products: Soltamox, Gemcitabine and other generic sterile injectable cytotoxic products, and Cancer support therapeutics. Soltamox (oral liquid tamoxifen), its first proprietary, FDA approved product, is a drug primarily used to treat breast cancer. Soltamox has been approved by the U.S. Food and Drug Administration ('FDA') for the treatment of breast cancer. Soltamox will be the only liquid formulation of tamoxifen available for sale in the United States. Soltamox is used mainly for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups. The Company is also focusing on the development and commercialization of generic sterile injectable cytotoxic products. The Company's agreement with Uman Pharma Inc. pursuant to which it received an exclusive license to import, sell, market and distribute Uman's gemcitabine lyophilized powder product in 200mg and 1g dosage sizes in the U.S. Gemcitabine went off patent in 2011 in the U.S. and is prescribed as first-line therapy for ovarian, breast, lung and pancreatic cancers. Currently, the Company has two main drug candidates advancing through clinical development with cleared Investigational New Drug applications from the FDA: KRN5500, a novel, non-narcotic/non-opioid for the treatment of neuropathic pain in patients with cancer; and DB959, a first-in-class drug candidate for the treatment of type 2 diabetes and dyslipidemia. The Company mainly competes with other pharmaceutical companies, biotechnology companies and other research and academic institutions. The Company's advertising, marketing and distribution of pharmaceutical products in the United States is subject to the regulation of United States Food, Drug and Cosmetic Act.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:PJUF has been successfully added to your 